Creative Planning lowered its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 6.1% during the second quarter, Holdings Channel reports. The fund owned 3,100 shares of the biopharmaceutical company’s stock after selling 201 shares during the period. Creative Planning’s holdings in Esperion Therapeutics were worth $143,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Teachers Advisors LLC boosted its stake in Esperion Therapeutics by 56.7% in the fourth quarter. Teachers Advisors LLC now owns 33,502 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 12,122 shares in the last quarter. Bank of Montreal Can boosted its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock worth $1,387,000 after buying an additional 921 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Esperion Therapeutics during the first quarter worth $961,000. Finally, Wells Fargo & Company MN boosted its stake in Esperion Therapeutics by 39.4% in the first quarter. Wells Fargo & Company MN now owns 11,602 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 3,282 shares in the last quarter. Institutional investors own 85.20% of the company’s stock.

Shares of Esperion Therapeutics, Inc. (NASDAQ ESPR) traded up 2.47% during trading on Friday, hitting $49.33. 912,599 shares of the company traded hands. The company has a 50-day moving average of $47.09 and a 200-day moving average of $35.27. Esperion Therapeutics, Inc. has a 52-week low of $9.40 and a 52-week high of $57.38. The stock’s market capitalization is $1.11 billion.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25. During the same quarter in the previous year, the business earned ($0.62) earnings per share. Equities analysts expect that Esperion Therapeutics, Inc. will post ($7.29) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Creative Planning Sells 201 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/creative-planning-sells-201-shares-of-esperion-therapeutics-inc-nasdaqespr/1479658.html.

A number of analysts have recently weighed in on ESPR shares. Jefferies Group LLC started coverage on shares of Esperion Therapeutics in a report on Monday, July 10th. They issued a “hold” rating and a $55.00 price target on the stock. Stifel Nicolaus restated a “buy” rating and issued a $60.00 price target (up from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. UBS AG restated a “buy” rating and issued a $57.00 price target (up from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Finally, Deutsche Bank AG started coverage on shares of Esperion Therapeutics in a report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $42.51.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.